Magnesium microspheres for liver cancer treatment
Part of Cancer clinical trials.
This study tests a new type of microsphere (tiny particles) made of magnesium that is biodegradable. It is used in chemoembolization (TACE) to block blood flow to liver tumors and deliver chemotherapy directly. This approach may help control tumors and could be an option for people who cannot have surgery or other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of liver cancer called hepatocellular carcinoma that is at a stage where chemoembolization (TACE) is appropriate, and you cannot or choose not to have surgery, liver transplant, or ablation.
- You are generally in good health (able to do daily activities) and your liver function is fair (Child-Pugh A or B).
- You have at least one untreated liver tumor that is at least 3 cm but not larger than 10 cm.
- If you have hepatitis B or C, you must be willing to take antiviral medication throughout the study.
- You will be asked to avoid other cancer treatments or embolization within 28 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ACE723, which is designed to specifically attack liver cancer cells while sparing healthy cells. It is for people with advanced liver cancer that has not responded to or has worsened after standard treatments that included immunotherapy.
This trial tests a treatment that delivers tiny radioactive beads directly to liver tumors through a tube. It is for people with one or a few small liver tumors that cannot be removed with surgery or destroyed with heat or cold. The goal is to shrink or control the tumors with fewer side effects.
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.
This trial compares two types of tiny beads used in a liver cancer treatment called TACE to see which works better. If you have liver cancer that needs TACE and your liver is still working fairly well, you may be able to join.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.